Positive impact of obesity on the prognosis of liver cirrhosis.
Dynapenia
Dynapenic obesity
Obesity
Obesity paradox
Pre‐sarcopenia
Sarcopenic obesity
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
03 May 2024
03 May 2024
Historique:
revised:
04
04
2024
received:
09
01
2024
accepted:
15
04
2024
medline:
3
5
2024
pubmed:
3
5
2024
entrez:
3
5
2024
Statut:
aheadofprint
Résumé
The study aims to determine the prognostic impact of obesity, sarcopenic obesity, and dynapenic obesity in patients with chronic liver disease. This retrospective observational study enrolled patients with chronic hepatitis (n = 746) and liver cirrhosis (n = 434) without hepatocellular carcinoma at entry. The patients were evaluated for sarcopenia and obesity between April 2016 and April 2022. Obesity was defined as a body mass index of ≥ 25 kg/m The mean observation period was 2.5 years. Obesity, sarcopenic obesity, and dynapenic obesity were found in 271 (45.5%), 17 (2.9%), and 21 (3.5%) men, and 261 (44.7%), 59 (10.1%), and 53 (9.1%) women, respectively. A multivariate Cox proportional hazards model revealed that Child-Pugh class, dynapenia (hazard ratio [HR] 3.89), elderly (≥ 65 years old) (HR 2.11), and obesity (HR 0.58) were independently associated with overall survival (OS). However, neither sarcopenic nor dynapenic obesity were associated with OS. In patients with cirrhosis, the OS of the obese group was significantly higher than that of the non-obese group. The effect of obesity on OS was significant in elderly patients, but not in younger patients. Sarcopenic and dynapenic obesity seem unrelated to the prognosis of patients with chronic liver disease. Obesity has a positive effect on the prognosis of elderly patients with cirrhosis.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The study aims to determine the prognostic impact of obesity, sarcopenic obesity, and dynapenic obesity in patients with chronic liver disease.
METHODS
METHODS
This retrospective observational study enrolled patients with chronic hepatitis (n = 746) and liver cirrhosis (n = 434) without hepatocellular carcinoma at entry. The patients were evaluated for sarcopenia and obesity between April 2016 and April 2022. Obesity was defined as a body mass index of ≥ 25 kg/m
RESULTS
RESULTS
The mean observation period was 2.5 years. Obesity, sarcopenic obesity, and dynapenic obesity were found in 271 (45.5%), 17 (2.9%), and 21 (3.5%) men, and 261 (44.7%), 59 (10.1%), and 53 (9.1%) women, respectively. A multivariate Cox proportional hazards model revealed that Child-Pugh class, dynapenia (hazard ratio [HR] 3.89), elderly (≥ 65 years old) (HR 2.11), and obesity (HR 0.58) were independently associated with overall survival (OS). However, neither sarcopenic nor dynapenic obesity were associated with OS. In patients with cirrhosis, the OS of the obese group was significantly higher than that of the non-obese group. The effect of obesity on OS was significant in elderly patients, but not in younger patients.
CONCLUSIONS
CONCLUSIONS
Sarcopenic and dynapenic obesity seem unrelated to the prognosis of patients with chronic liver disease. Obesity has a positive effect on the prognosis of elderly patients with cirrhosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Woodrow G. Body composition analysis techniques in the aged adult: indications and limitations. Curr. Opin. Clin. Nutr. Metab. Care 2009; 12: 8–14.
Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr. Opin. Clin. Nutr. Metab. Care 2008; 11: 693–700.
Zoico E, Di Francesco V, Guralnik JM et al. Physical disability and muscular strength in relation to obesity and different body composition indexes in a sample of healthy elderly women. Int. J. Obes. Relat. Metab. Disord. 2004; 28: 234–241.
Di Francesco V, Baggio E, Mastromauro M et al. Obesity and gastro‐esophageal acid reflux: physiopathological mechanisms and role of gastric bariatric surgery. Obes. Surg. 2004; 14: 1095–1102.
Tian S, Xu Y. Association of sarcopenic obesity with the risk of all‐cause mortality: a meta‐analysis of prospective cohort studies. Geriatr. Gerontol. Int. 2016; 16: 155–166.
Wong RJ, Aguilar M, Cheung R et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148: 547–555.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐ analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
Li J, Zou B, Yeo YH et al. Prevalence, incidence, and outcome of non‐alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta‐analysis. Lancet Gastroenterol. Hepatol. 2019; 4: 389–398.
Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2018; 15: 11–20.
Enomoto H, Ueno Y, Hiasa Y et al. The transition in the etiologies of hepatocellular carcinoma‐complicated liver cirrhosis in a nationwide survey of Japan. J. Gastroenterol. 2021; 56: 158–167.
Karagozian R, Derdak Z, Baffy G. Obesity‐associated mechanisms of hepatocarcinogenesis. Metabolism 2014; 63: 607–617.
Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis‐related death or hospitalization? A population‐based cohort study. Gastroenterology. 2003; 125: 1053–1059.
Karagozian R, Bhardwaj G, Wakefield DB, Baffy G. Obesity paradox in advanced liver disease: obesity is associated with lower mortality in hospitalized patients with cirrhosis. Liver Int. 2016; 36: 1450–1456.
Montano‐Loza AJ, Angulo P, Meza‐Junco J et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J. Cachexia. Sarcopenia Muscle 2016; 7: 126–135.
Lainscak M, Haehling SV, Doehner W, Anker SD. The obesity paradox in chronic disease: facts and numbers. J. Cachexia. Sarcopenia Muscle 2012; 3: 1–4.
Hastie CE, Padmanabhan S, Slack R et al. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur. Heart J. 2010; 31: 222–226.
Carnethon MR, Chavez PJDD, Biggs ML et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012; 308: 581–590.
Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Sarcopenic Obesity in liver cirrhosis: possible mechanism and clinical impact. Int. J. Mol. Sci. 2021; 22: 1917.
Eslamparast T, Montano‐Loza AJ, Raman M, Tandon P. Sarcopenic obesity in cirrhosis—the confluence of 2 prognostic titans. Liver Int. 2018; 38: 1706–1717.
Cruz‐Jentoft AJ, Bahat G, Bauer J et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16–31.
Asahina Y. Drafting Committee for Hepatitis Management guidelines, the Japan Society of Hepatology. JSH Guidelines for the management of hepatitis C virus infection, 2019 ipdate; protective effect of antiviral therapy against hepatocarcinogenesis. Hepatol. Res. 2020; 50: 775–790.
Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis B virus infection: 2019 update. Hepatol. Res. 2020; 50: 892–923.
Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 2023; 79: 1542–1556.
Yoshiji H, Nagoshi S, Akahane T et al. Evidence‐based clinical practice guidelines for liver cirrhosis 2020. Hepatol. Res. 2021; 51: 725–749.
Endo K, Sato T, Kakisaka K, Takikawa Y. Calf and arm circumference as simple markers for screening sarcopenia in patients with chronic liver disease. Hepatol. Res. 2021; 51: 176–189.
The Asia‐Pacific Perspective. Redefining Obesity and its Treatment. Geneva, Switzerland: World Health Organization, 2000.
Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol. Res. 2016; 46: 951–963.
Kanda Y. Investigation of the freely available easy‐to‐use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452–458.
Berzigotti A, Garcia‐Tsao G, Bosch J et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology 2011; 54: 555–561.
Zheng W, McLerran DF, Rolland B et al. Association between body‐mass index and risk of death in more than 1 million Asians. N. Engl. J. Med. 2011; 364: 719–729.
Snih SA, Ottenbacher KJ, Markides KS, Kuo YF, Eschbach K, Goodwin JS. The effect of obesity on disability vs mortality in older Americans. Arch. Intern. Med. 2007; 167: 774–780.
Uretsky S, Messerli FH, Bangalore S et al. Obesity paradox in patients with hypertension and coronary artery disease. Am. J. Med. 2007; 120: 863–870.
Lainscak M, von Haehling S, Doehner W et al. Body mass index and prognosis in patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. J. Cachexia. Sarcopenia Muscle 2011; 2: 81–86.
Kalantar‐Zadeh K, Streja E, Kovesdy CP et al. The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin. Proc. 2010; 85: 991–1001.
Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N. Engl. J. Med. 2006; 355: 763–778.
Enomoto H, Ueno Y, Hiasa Y et al. Transition in the etiology of liver cirrhosis in Japan: a nationwide survey. J. Gastroenterol. 2020; 55: 353–362.
Tateishi R, Uchino K, Fujiwara N et al. A nationwide survey on non‐B, non‐C hepatocellular carcinoma in Japan: 2011‐2015 update. J. Gastroenterol. 2019; 54: 367–376.
Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M. Branched‐chain amino acids as a protein‐ and energy‐source in liver cirrhosis. Biochem. Biophys. Res. Commun. 2004; 313: 405–409.
Schneeweiss B, Graninger W, Ferenci P et al. Energy metabolism in patients with acute and chronic liver disease. Hepatology 1990; 11: 387–393.
Chen CJ, Wang LC, Kuo HT, Fang YC, Lee HF. Significant effects of late evening snack on liver functions in patients with liver cirrhosis: A meta‐analysis of randomized controlled trials. J. Gastroenterol. Hepatol. 2019; 34: 1143–1152.
Muto Y, Sato S, Watanabe A et al. Effects of oral branched‐chain amino acid granules on event‐free survival in patients with liver cirrhosis. Clin. Gastroenterol. Hepatol. 2005; 3: 705–713.
Ebadi M, Tandon P, Moctezuma‐Velazquez C et al. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis. J. Hepatol. 2018; 69: 608–616.
Sakamaki A, Yokoyama K, Koyama K et al. Obesity and accumulation of subcutaneous adipose tissue are poor prognostic factors in patients with alcoholic liver cirrhosis. PLoS ONE 2020; 15: e0242582.
Zhu M, Li H, Yin Y et al. U‐shaped relationship between subcutaneous adipose tissue index and mortality in liver cirrhosis. J. Cachexia. Sarcopenia Muscle 2023; 14: 508–516.
Hozawa A, Hirata T, Yatsuya H et al. Association between body mass index and all‐cause death in Japanese population: Pooled individual participant data analysis of 13 cohort studies. J. Epidemiol. 2019; 29: 457–463.
Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all‐cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta‐analysis. JAMA 2013; 309: 71–82.
Sinclair M, Chapman B, Hoermann R et al. Handgrip strength adds more prognostic value to the model for end‐stage liver disease score than imaging‐based measures of muscle mass in men with cirrhosis. Liver Transpl. 2019; 25: 1480–1487.
Kappus MR, Wegermann K, Bozdogan E et al. Use of skeletal muscle index as a predictor of wait‐list mortality in patients with end‐stage liver disease. Liver Transpl. 2020; 26: 1090–1099.
Hanai T, Shiraki M, Imai K et al. Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: a sex‐stratified analysis. Hepatol. Res. 2019; 49: 1414–1426.
Endo K, Kuroda H, Kanazawa J et al. Impact of grip strength in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Cancers (Basel). 2020; 12: 2146.